Jan Philipp Radtke, MD, MBA, presented “Clinical Evaluation and Management of Men with Localized and Recurrent Prostate Cancer” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 21, 2023.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Radtke, Jan Philipp “Clinical Evaluation and Management of Men with Localized and Recurrent Prostate Cancer.” September 21, 2023. Accessed Aug 2024. https://grandroundsinurology.com/clinical-evaluation-and-management-of-men-with-localized-and-recurrent-prostate-cancer/
Clinical Evaluation and Management of Men with Localized and Recurrent Prostate Cancer – Summary
Jan Philipp Radtke, MD, MBA, addresses the clinical evaluation and management of men with localized and recurrent prostate cancer, emphasizing a comprehensive and personalized approach to treatment.
Dr. Radtke discusses how advanced imaging techniques, such as multiparametric MRI (mpMRI) and PET imaging (e.g., PSMA-PET), provide detailed anatomical and functional information. He also addresses management strategies for recurrent prostate cancer including salvage radiation therapy, salvage surgery (e.g., radical prostatectomy), systemic therapies such as androgen deprivation therapy (ADT), or novel targeted therapies.
Dr. Radtke emphasizes the importance of multidisciplinary collaboration in managing complex cases of prostate cancer. Collaboration among urologists, radiation oncologists, medical oncologists, and imaging specialists ensures a coordinated approach to treatment planning and monitoring. Regular monitoring through PSA tests and imaging assessments allows for early detection of treatment response or disease progression, enabling timely adjustments to therapeutic strategies.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
ABOUT THE AUTHOR
Professor Dr. med. Jan Philipp Radtke is the Deputy Clinical Director and Senior Physician in the Department of Urology at Heinrich-Heine University Düsseldorf, as well as a Professor of Urology and MBA. He has been a Consultant in urology and Assistant Professor of Urology in the Department of Urology at the University Hospital Essen, Germany, since 2019, where he specialized in uro-oncology. Dr. Radtke is also a postdoctoral fellow in the Department of Radiology at the German Cancer Research Center in Heidelberg, Germany, and completed an MBA in medicine management at Westfälische Wilhelms-University in Münster, Germany, in 2021.
Dr. Radtke earned his medical degree from the University of Cologne, Kantonsspital St Gallen, Switzerland, and Eidgenössische Technische Hochschule Zürich, Switzerland, in 2011. He completed his residency in the Department of Urology at Heidelberg University Medical Center and a postdoctoral fellowship at the German Cancer Research Center from 2014 to 2016. In 2017, he was named a Fellow of the European Board of Urologists (FEBU) and earned the venia legendi for urology in 2018. He previously served as a Consultant in the Department of Urology at Heidelberg University from 2017 to 2019.
Dr. Radtke's research interests include MRI of the prostate and pelvis, MRI/transrectal ultrasound (TRUS) fusion biopsy, risk stratification of prostate cancer, prediction of extracapsular extension prior to radical prostatectomy, and PSMA-PET imaging. Clinically, he focuses on the diagnosis and surgical (open and robotic) and systemic treatment of renal and prostate malignancies. He has co-authored more than 70 peer-reviewed papers, reviews, and multiple book chapters.
